GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (NAS:ATHE) » Definitions » Price-to-Owner-Earnings

Alterity Therapeutics (Alterity Therapeutics) Price-to-Owner-Earnings : (As of May. 02, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Alterity Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-02), Alterity Therapeutics's share price is $2.20. Alterity Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Alterity Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


ATHE's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.25
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-02), Alterity Therapeutics's share price is $2.20. Alterity Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-2.30. Therefore, Alterity Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-02), Alterity Therapeutics's share price is $2.20. Alterity Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-2.41. Therefore, Alterity Therapeutics's PE Ratio without NRI for today is At Loss.


Alterity Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Alterity Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alterity Therapeutics Price-to-Owner-Earnings Chart

Alterity Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alterity Therapeutics Quarterly Data
Dec17 Jun18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alterity Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Alterity Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alterity Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's Price-to-Owner-Earnings falls into.



Alterity Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Alterity Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.20/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alterity Therapeutics  (NAS:ATHE) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Alterity Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Alterity Therapeutics (Alterity Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

Alterity Therapeutics (Alterity Therapeutics) Headlines